- POAI’s
Helomics division progresses toward critical milestone in CancerQuest2020
initiative
- Predictive
models immensely valuable to pharmaceutical industry, improving drug
evaluation without incurring high laboratory costs
- POAI
is bringing precision medicine to the treatment of cancer for patients of
today and tomorrow
Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven
company focused on applying artificial intelligence (AI) to personalized
medicine and drug discovery, today announced continued progress by its Helomics
subsidiary toward the goal of developing an AI-driven predictive model of
ovarian cancer. This achievement will be a key milestone for the company’s
CancerQuest2020 initiative (http://ibn.fm/mENY6).
CancerQuest2020 is focused on building an AI-driven model of
ovarian cancer that will predict drug response and outcome leveraging Helomics’
huge knowledge base of tumor profiles. Predictive models embody the knowledge
from these profiles to create a “computational expert” or a “virtual patient”
that can be queried. Predictive models such as these are of high value to
pharmaceutical companies as they can be used to quickly select patients for
clinical trials and assess potential new drugs or biomarkers computationally
(“in silico”) before initiating expensive laboratory experiments. In short, Helomics’
predictive models will save time and money in the search for new targeted
therapies.
Using the power of AI, the model draws on data generated
from over 150,000 tumor cases obtained from over 15 years of clinical testing
on living patient tumors, bringing together valuable multi-omic data, i.e. drug
response, genomic (mutations), transcriptomic (gene expression) and tissue-omic
(tumor pathology) profiles to predict drug response and outcome.
“Despite some headwinds imposed by the current COVID-19
pandemic, the Helomics team has been working diligently to meet both our
clinical testing priorities for ovarian cancer patients and their oncologists,
as well as maintaining progress on data generation for CCQ2020,” Helomics
President Gerald Vardzel stated in a news release (http://ibn.fm/957XJ). “Also, we received our formal letter
of compliance today for our CLIA (Clinical Laboratory Improvement Amendments)
recertification survey conducted on March 10, 2020. Results of this survey
showed all requirements were met and that we were in full compliance with
applicable regulations,” added Helomics medical director and vice president of
operations and pathology services Dr. Arlette Uihlein.
“In a true team effort across the company we have made solid
progress on our CCQ2020 milestones this quarter; we ramped up our sequencing
effort as part of our UPMC-Magee collaboration; initiated further digitization
of our histopathology slide collection; renewed our collaboration with Genomics
England 100,000 genomes project and completed development of our AI model build
framework so we can train millions of potential models at scale using cloud
resources,” indicated Helomics CTO Dr. Mark Collins.
POAI is bringing precision medicine, or tailored
medical treatment using the individual characteristics of each patient, to the
treatment of cancer. Through the company’s Helomics division, the company
leverages its unique, clinically validated patient derived (PDx) smart tumor
profiling platform to provide oncologists with a road map to help individualize
therapy. In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer tumors to build AI-driven
models of tumor drug response to improve outcomes for the patients of today and
tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from start-ups
to established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
